Komori
Results presentation4523Eisai Co.,Ltd.Pharmaceuticals

Reference Materials for Second-Quarter (Interim-Period) Financial Results for Fiscal 2026 (Fiscal Year Ending March 2027)

The first half of FY2026 generated higher revenue and profit, driven by increased sales of the company's mainstay drugs and the positive effect of the weaker yen. The full-year forecast was left unchanged. Revenue for the interim period was ¥470.0 billion and operating profit was ¥41.4 billion.

Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
699
¥100 million (year-on-year increase in revenue)
Wording
Conditional
How definitive the wording is.

Contents of this document

Supplementary Materials to the Earnings SummarySecond quarter (interim period) of the fiscal year ending March 20269 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales4,700 Hundreds of millions of yen+17.5%
Operating profit414 Hundreds of millions of yen+20.4%
Ordinary income¥416 billion +12.7%IFRS profit before tax for the interim period
Net income¥299 100 million +21.5%interim profit attributable to owners of the parent
Selling, general and administrative expenses2,352 Hundreds of millions of yen
Gross Profit Margin
Rate77.7%
Operating profit margin
Rate8.8%
Results for the three months of the current quarter
Revenue
2,356 Hundreds of millions of yen+19.4%
Operating profit
167 Hundreds of millions of yen+22.1%
Quarterly profit attributable to owners of the parent
117 Hundreds of millions of yen+15.1%
Full-year earnings forecast
Revenue
8,835 Hundreds of millions of yen
Operating profit
700 Hundreds of millions of yen
Pretax profit
740 Hundreds of millions of yen
Profit attributable to owners of the parent
523 Hundreds of millions of yen
EPS
185 Yen
DPS
160 Yen
Research and Development Expenses
1,640 Hundreds of millions of yen
Capital expenditures
300 Hundreds of millions of yen
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Revenue53.2%
Operating profit59.2%
Core operating profit61.5%
Pretax profit56.3%
Profit attributable to owners of the parent57.2%
Pharmaceutical business revenue53.1%
Japan pharmaceutical business revenue50.0%
Americas pharmaceutical business revenue53.2%
China pharmaceutical business revenue56.2%
EMEA pharmaceutical business revenue59.8%
EAGS pharmaceutical business revenue50.1%
Other businesses revenue58.6%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Impact of foreign exchange movements on revenue
332.2 Hundreds of millions of yen
Impact of foreign exchange movements on operating profit
35.4 Hundreds of millions of yen
Lenvima profit-sharing payment amount
Current fiscal year
897 Hundreds of millions of yen
Same period of the previous year
756 Hundreds of millions of yen
Amount borne by alliance partners
Current fiscal year
111 Hundreds of millions of yen
Same period of the previous year
152 Hundreds of millions of yen
Adjustment from operating profit to core operating profit
Gains and losses on the sale of property, plant and equipment
0 Hundreds of millions of yen
Employee termination benefit expense arising from business restructuring
-1 Hundreds of millions of yen
Significant damages or settlement costs arising from litigation and other matters
17 Hundreds of millions of yen
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
USD/JPY¥153.00
EUR/JPYJPY 180.00
GBP/JPY¥205.00
CNY/JPY¥22.50/CNY
New initiatives
  • Approval in the United States, China and Japan of the initial treatment regimen for the Leqembi subcutaneous auto-injector (500 mg)
  • U.S. approval of the combination therapy of Lenvima and belzutifan
  • Japanese approval of the 1-year-old indication for Movicol in the treatment of chronic constipation
  • Acquisition of development, regulatory and commercialization rights for taletrectinib in Europe and other regions
Key KPIsA metric the company considers important as a management benchmark.
  • Core products (3L) revenue2,958 Hundreds of millions of yen
    Year on year against the same period last year24.9%
  • LENVIMA/Kisplyx revenue1,948 Hundreds of millions of yen
    Year on year against the same period last year17.0%
  • Leqembi revenue615 Hundreds of millions of yen
    Year on year against the same period last year49.7%
  • Dayvigo revenue395 Hundreds of millions of yen
    Year on year against the same period last year35.7%
  • Consolidated headcount10,439 people
Segment results
Japan
Revenue
1,167 Hundreds of millions of yen+3.7%
Segment profit
366 Hundreds of millions of yen+8.9%
Americas
Revenue
1,792 Hundreds of millions of yen+26.5%
Segment profit
466 Hundreds of millions of yen+55.6%
China
Revenue
826 Hundreds of millions of yen+24.7%
Segment profit
329 Hundreds of millions of yen+25.1%
EMEA
Revenue
437 Hundreds of millions of yen+12.6%
Segment profit
101 Hundreds of millions of yen+59.0%
EAGS
Revenue
399 Hundreds of millions of yen+17.0%
Segment profit
141 Hundreds of millions of yen+12.4%
Other businesses
Revenue
79 Hundreds of millions of yen+17.2%
Segment profit
25 Hundreds of millions of yen-19.2%
Financial targets
ROE
Full-year forecast5.9%
Adjusted ROIC
Full-year forecast8.7%
Number of employees
Consolidated10,439 people
Individual2,997 people
Capital expenditures
¥113 billion interim actual, capital expenditures
Annual Dividend
Annual dividend per share¥160.0
Interim¥80.0
End of period¥80.0
Contents of this document
ItemDetails
Document typeSupplementary Materials to the Earnings Summary
Fiscal Period CoveredSecond quarter (interim period) of the fiscal year ending March 2026
Net Sales4,700 Hundreds of millions of yen (YoY +17.5%)
Operating profit414 Hundreds of millions of yen (YoY +20.4%)
Ordinary income¥416 billion (IFRS profit before tax for the interim period) (YoY +12.7%)
Net income¥299 100 million (interim profit attributable to owners of the parent) (YoY +21.5%)
Gross Profit MarginRate 77.7% / Year-on-year change (points) Not disclosed
Operating profit marginRate 8.8% / Year-on-year change (points) Not disclosed
Selling, general and administrative expenses2,352 Hundreds of millions of yen
Results for the three months of the current quarterRevenue 2,356 Hundreds of millions of yen (YoY +19.4%) / Operating profit 167 Hundreds of millions of yen (YoY +22.1%) / Quarterly profit attributable to owners of the parent 117 Hundreds of millions of yen (YoY +15.1%)
Full-year earnings forecastRevenue 8,835 Hundreds of millions of yen / Operating profit 700 Hundreds of millions of yen / Pretax profit 740 Hundreds of millions of yen / Profit attributable to owners of the parent 523 Hundreds of millions of yen / EPS 185 Yen / DPS 160 Yen / Research and Development Expenses 1,640 Hundreds of millions of yen / Capital expenditures 300 Hundreds of millions of yen
Progress against full-year forecastRevenue 53.2% / Operating profit 59.2% / Core operating profit 61.5% / Pretax profit 56.3% / Profit attributable to owners of the parent 57.2% / Pharmaceutical business revenue 53.1% / Japan pharmaceutical business revenue 50.0% / Americas pharmaceutical business revenue 53.2% / China pharmaceutical business revenue 56.2% / EMEA pharmaceutical business revenue 59.8% / EAGS pharmaceutical business revenue 50.1% / Other businesses revenue 58.6%
Segment resultsJapan Revenue 1,167 Hundreds of millions of yen (YoY +3.7%) / Segment profit 366 Hundreds of millions of yen (YoY +8.9%) / Americas Revenue 1,792 Hundreds of millions of yen (YoY +26.5%) / Segment profit 466 Hundreds of millions of yen (YoY +55.6%) / China Revenue 826 Hundreds of millions of yen (YoY +24.7%) / Segment profit 329 Hundreds of millions of yen (YoY +25.1%) / EMEA Revenue 437 Hundreds of millions of yen (YoY +12.6%) / Segment profit 101 Hundreds of millions of yen (YoY +59.0%) / EAGS Revenue 399 Hundreds of millions of yen (YoY +17.0%) / Segment profit 141 Hundreds of millions of yen (YoY +12.4%) / Other businesses Revenue 79 Hundreds of millions of yen (YoY +17.2%) / Segment profit 25 Hundreds of millions of yen (YoY -19.2%)
Breakdown of Factors Affecting the ChangeImpact of foreign exchange movements on revenue 332.2 Hundreds of millions of yen / Impact of foreign exchange movements on operating profit 35.4 Hundreds of millions of yen / Lenvima profit-sharing payment amount Current fiscal year 897 Hundreds of millions of yen / Same period of the previous year 756 Hundreds of millions of yen / Amount borne by alliance partners Current fiscal year 111 Hundreds of millions of yen / Same period of the previous year 152 Hundreds of millions of yen / Adjustment from operating profit to core operating profit Gains and losses on the sale of property, plant and equipment 0 Hundreds of millions of yen / Employee termination benefit expense arising from business restructuring -1 Hundreds of millions of yen / Significant damages or settlement costs arising from litigation and other matters 17 Hundreds of millions of yen
Key KPIsIndicator name Core products (3L) revenue / Value 2,958 Hundreds of millions of yen / Year on year against the same period last year 24.9%, Indicator name LENVIMA/Kisplyx revenue / Value 1,948 Hundreds of millions of yen / Year on year against the same period last year 17.0%, Indicator name Leqembi revenue / Value 615 Hundreds of millions of yen / Year on year against the same period last year 49.7%, Indicator name Dayvigo revenue / Value 395 Hundreds of millions of yen / Year on year against the same period last year 35.7%, Indicator name Consolidated headcount / Value 10,439 people / Year on year against the same period last year Not disclosed
Number of employeesConsolidated 10,439 people / Individual 2,997 people
Assumptions Underlying the Business OutlookUSD/JPY ¥153.00 / EUR/JPY JPY 180.00 / GBP/JPY ¥205.00 / CNY/JPY ¥22.50/CNY
Financial targetsROE Actual results Not disclosed / Full-year forecast 5.9% / Adjusted ROIC Actual results Not disclosed / Full-year forecast 8.7%
Annual DividendAnnual dividend per share ¥160.0 / Interim ¥80.0 / End of period ¥80.0
Capital expenditures¥113 billion (interim actual, capital expenditures)
New initiativesApproval in the United States, China and Japan of the initial treatment regimen for the Leqembi subcutaneous auto-injector (500 mg), U.S. approval of the combination therapy of Lenvima and belzutifan, Japanese approval of the 1-year-old indication for Movicol in the treatment of chronic constipation, Acquisition of development, regulatory and commercialization rights for taletrectinib in Europe and other regions
Items this document does not state (10)
Self-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In addition to growth in the anticancer drug Lenvima, the Alzheimer's disease treatment Leqembi and the insomnia treatment Dayvigo, the weaker yen boosted revenue. Selling, general and administrative expenses increased due to investment in Leqembi, while research and development expenses increased due to investment in E2814, E2086 and other projects.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Reference Materials for Second-Quarter (Interim-Period) Financial Results for Fiscal 2026 (Fiscal Year Ending March 2027) | Eisai Co.,Ltd. (4523) timely disclosure | Komori